Vanda Pharmaceuticals has launched NEREUS™ (tradipitant), the first new prescription drug in over 40 years for preventing motion sickness-induced vomiting in adults. Approved by the FDA in December 2025, NEREUS™ works by blocking NK-1 receptors in the brain to stop vomiting triggered by motion. It is available nationwide through pharmacies and a direct-to-consumer platform at nereus.us, offering a discounted price of $85 per dose compared to the standard $255. This new treatment addresses a common condition affecting up to 30% of American adults during travel and represents a significant advancement in motion sickness care.
BlackRock, Inc. has reported that its direct and indirect ownership in Orion Oyj has dropped below the 5% threshold as of June 15, 2026. This change requires a formal disclosure under Finnish securities law. The reduction in BlackRock's stake may aff...
On June 15, 2026, BlackRock, Inc. and its funds reduced their total holdings in Orion Corporation to below 5% of the company's shares and voting rights. This change was disclosed under the Finnish Securities Market Act, indicating a decrease from a p...
US stock futures showed mixed results with the S&P 500 slightly down while the Dow Jones and Nasdaq 100 edged higher following a recent rally. The market reacted to a preliminary US-Iran agreement aimed at extending a ceasefire and reopening the Stra...
MindWalk Holdings Corp. emphasizes the importance of a connected, trustworthy biological data layer over AI model size in drug discovery. The company launched ReefIQ™, a biological context layer, and LensAI™, a reasoning platform, aiming to reduce co...
Space Exploration Technologies Corp. (SpaceX) saw its shares surge over 11% in premarket trading, pushing its market capitalization close to $3 trillion, surpassing Amazon to become the fifth-largest company globally. This rapid valuation increase ha...
